patient adherence | pharmaphorum

Skip to main content

Friday 25 April 2025

twitter linkedin facebook rss

User account menu

Subscribe

Channels

Content type

Categories

Categories

Sort by

Order

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

close

Channels

Content type

Categories

Categories

Sort by

Order

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

Sign up

twitter linkedin facebook rss

Sign in

patient adherence

Patients

pharmaphorum podcast episode 95a

Creating behavioural change through incremental, small steps

In this latest episode of the pharmaphorum podcast, web editor Nicole Raleigh speaks with Sarah Watters, senior consultant at Wellth, a company devoted to improving the health of people wit

Patients

medication

Patient adherence – the key to restoring trust in pharma

Medication is a staple of modern medicine, with almost 50% of adults in the United Sta

R&D

neuron or nerve cell

Novartis’ Kesimpta, ECTRIMS 2022, and relapsing multiple scl...

Having presented new data at last year’s European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Annual Meeting – where the safety and efficacy of Novartis’ Kesimpta (

Sales & Marketing

budgets

Why script-to-dispense conversion will take centre stage in ...

With the US economy teetering on a recession, sales and marketing budgets are expected to take a hit among businesses across sectors.

Views & Analysis

stethoscope

The power of self-management to target gaps in chronic disea...

The time of healthcare professionals is limited, but systems often rely on them as the principal means to help patients with chronic diseases.

Editor's Picks

Trump pledges drug price cuts – and action on 'pill penalty'

Lilly soars on first data for oral obesity candidate

Norgine on a growth charge again with Theravia takeover deal

FDA clears first migraine DTx from Click Therapeutics

After delay, Alzheimer's drug Leqembi gets green light in EU

News

Dr Yu Xia, founder, chairwoman, president and chief executive of Akeso

Akeso PD-1 inhibitor cleared as Keytruda challenger advances

Akeso has bagged an FDA approval for its PD-1 inhibitor penpulimab and reported new data on highly-touted PD-1/VEGF bispecific ivonescimab.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Abstract visual of head

Sponsored

Health Trends 2025: Reimagining What's Possible

Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Subscribe

rss facebook linkedin twitter

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2025, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2025, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company